AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Risk Stratification, Imaging, and Treatment of High-Risk Squamous Cell Carcinoma

Description

The speaker, a Mohs surgeon and cutaneous oncologist, reviewed how to recognize and manage high-risk cutaneous squamous cell carcinoma, emphasizing that small lesions can behave aggressively, especially in high-risk sites such as the ears, lips, eyes, neck, genitalia, scars, and preauricular area. Important clinical risk factors include immunosuppression (especially transplant recipients and patients with CLL), rapid growth, prior radiation, inflammatory appearance, poor differentiation, perineural invasion, lymphovascular invasion, recurrence, and deep invasion. He noted that AJCC and Brigham and Women’s staging are useful but miss some patients with poor outcomes, particularly T2A tumors with minor risk factors, and he highlighted newer tools such as risk models, a recent EADO transplant-focused classification, and gene expression profiling. For imaging, he generally recommends CT of the head/neck, especially when there is bony invasion, T2A-high, T2B, or T3 disease, and sometimes serial ultrasound depending on expertise. Imaging can change management and may prompt referral to ENT/head-and-neck oncology, radiation, or other treatments. He also discussed sentinel lymph node biopsy, which is most worth considering in T2B and T3 tumors, and explained how GEP results may influence decisions about imaging and adjuvant radiation when standard staging does not fully capture risk. Overall, he stressed combining standard staging with clinical judgment to guide surgery, imaging, biopsy, radiation, and immunotherapy when needed.

View more

Conclusions

  • Traditional staging systems for cutaneous squamous cell carcinoma are useful but miss important clinical and biologic risk factors, so they should not be used alone to judge prognosis.
  • High-risk features such as immunosuppression, rapid growth, poor differentiation, perineural invasion, lymphovascular invasion, recurrence, and deep or aggressive tumors are strongly associated with worse outcomes.
  • Small or apparently low-stage tumors can still behave aggressively, especially when multiple minor risk factors are present.
  • Patients with T2b and T3 disease, and some selected T2a high-risk tumors, warrant additional workup such as imaging and consideration of nodal staging.
  • Baseline and surveillance imaging can uncover occult disease and often changes management in high-risk SCC.
  • Sentinel lymph node biopsy has a meaningful positivity rate in high-risk SCC and should be considered in selected patients, particularly those with T2b or T3 disease.
  • Gene expression profiling may improve risk stratification beyond standard staging and can help guide decisions about imaging, radiation, and other adjuvant treatments.
  • Transplant recipients and other immunosuppressed patients need separate or expanded risk assessment because standard staging underestimates their danger.
  • Large-caliber perineural invasion, satellitosis/in-transit metastasis, and recurrent tumors identify particularly poor-prognosis subsets.
  • Many SCC-related deaths arise from uncontrolled locoregional disease rather than distant metastasis, emphasizing the need for early aggressive local management.
  • Surgery remains the cornerstone of treatment when feasible, but high-risk cases often require multidisciplinary care, adjuvant radiation, nodal evaluation, immunotherapy, or referral to head and neck oncology.
  • Clinical judgment and patient preferences still matter, but when risk is high, clinicians should escalate workup and follow-up rather than rely on tumor size alone.
  • Tolkachjov, S.N., Brewer, J.D. (2018). Skin Cancers Associated with Lymphoid Malignancies. In: Colegio, O. (eds) Skin Diseases in the Immunosuppressed. Springer, Cham. https://doi.org/10.1007/978-3-319-68790-2_7#10.1007/978-3-319-68790-2_7
  • J Am Acad Dermatol. 2023 May;88(5):1209-1211. doi: 10.1016/j.jaad.2023.01.012. Epub 2023 Jan 18. Perioperative imaging for high-stage cutaneous squamous cell carcinoma helps guide management in nearly a third of cases: A single-institution retrospective cohort.#10.1016/j.jaad.2023.01.012
  • Risk of recurrence, metastasis, and death for cutaneous squamous cell carcinomas with solitary large caliber perineural invasion: A multicenter cohort study. J Am Acad Dermatol. 2026 Epub 2025 Oct 17.#10.1016/j.jaad.2025.10.054
  • Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
  • Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.#10.58837/chula.the.2000.255
  • Validation of Current Staging Systems in HNCSCC: A Multinational Cohort Study.
  • Identifying the impact of minor risk factors in Brigham and Women’s Hospital stage T1 cutaneous squamous cell carcinomas on risk of poor outcomes: A retrospective cohort study.#10.1016/j.jaad.2025.02.052
  • Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma.#10.1001/jamadermatol.2025.0128
  • Lymphovascular invasion is an independent predictor of metastasis and disease-specific death in cutaneous squamous cell carcinoma: A multicenter retrospective study.#10.1016/j.jaad.2025.04.029
  • Satellitosis/in-transit metastasis in cutaneous squamous cell carcinoma: Risk factors and the prognostic significance.#10.1001/jamadermatol.2022.0001
  • Detection of subclinical disease with baseline and surveillance imaging in high-risk cutaneous squamous cell carcinomas.#10.1016/j.jaad.2019.10.067
  • Outcomes of Sentinel Lymph Node Biopsy for Primary Cutaneous Squamous Cell Carcinoma of the Head and Neck.#10.1177/0194599813496044a159
  • Nodal staging of high-risk cutaneous squamous cell carcinoma.
  • Rates of Upstaging, Between Diagnosis and Surgery, and Clinical Management of Metastatic Cutaneous Squamous Cell Carcinoma: A Case-Control Study.#10.1097/dss.0000000000003224
  • riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.#10.1007/978-3-662-47081-7_1
  • EADO classification of difficult-to-treat cutaneous squamous cell carcinoma in transplant recipients.#10.1111/jdv.70317
  • Patterns of disease-specific death from cutaneous squamous cell carcinoma: A multicenter retrospective cohort.#10.1016/j.jaad.2025.10.031
  • Recurrent status is associated with poor outcomes in cutaneous squamous cell carcinoma.#10.1007/978-3-662-47081-7_1
  • Identifying Brigham and Women’s Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes.#10.1016/j.jaad.2021.11.046
  • SLNB in cutaneous SCC: A review of the current state of literature and the direction for the future.#10.1016/j.jaad.2017.04.922
  • Clinical Versus Histologic Margins for Cutaneous Squamous Cell Carcinoma: Comparing Outcomes for High-Risk Tumors Treated With Mohs Micrographic Surgery.#10.1097/dss.0000000000004324
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Squamous Cell Skin Cancer, Version 2.2025 — February 7, 2025.